‘Celltrion’ becomes top in spending R&D expenses

Published: 2016-11-25 14:43:40

Updated: 2016-11-25 14:43:40

The KOSDAQ listed pharmaceutical companies’ average R&D expense/sales rate in the 3^rd quarter exceeded 10%, and the one for KOSPI listed pharmaceutical companies did not reach 10%.

According to the Yakup Shinmoon’s(www.yakup.com) analysis result of the 37 KOSPI and 29 KOSDAQ listed pharmaceutical companies’ (total 66 companies) collective R&D expenses in the 3^rd quarter, the growth rate of R&D...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.